Alkermes plc or Amneal Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?

SG&A Cost Management: Alkermes plc vs. Amneal Pharmaceuticals, Inc.

In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. From 2014 to 2023, Alkermes plc and Amneal Pharmaceuticals, Inc. have shown distinct approaches to handling these costs. Alkermes plc consistently reported higher SG&A expenses, peaking at approximately 690 million in 2023, reflecting a 245% increase from 2014. In contrast, Amneal Pharmaceuticals, Inc. demonstrated a more conservative growth, with SG&A expenses rising by about 408% over the same period, reaching around 430 million in 2023.

This data suggests that while Alkermes plc invests heavily in SG&A, potentially to drive growth and market presence, Amneal Pharmaceuticals, Inc. opts for a more restrained approach, possibly focusing on efficiency and cost control. Understanding these strategies provides valuable insights into each company's operational priorities and financial health.